abrdn Life Sciences Investors (NYSE:HQL) Holdings Lifted by LPL Financial LLC

LPL Financial LLC grew its position in abrdn Life Sciences Investors (NYSE:HQL) by 14.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 328,402 shares of the company’s stock after purchasing an additional 41,307 shares during the period. LPL Financial LLC owned approximately 1.14% of abrdn Life Sciences Investors worth $4,167,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Flagship Harbor Advisors LLC boosted its holdings in shares of abrdn Life Sciences Investors by 36.1% in the first quarter. Flagship Harbor Advisors LLC now owns 340,877 shares of the company’s stock valued at $4,326,000 after acquiring an additional 90,436 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of abrdn Life Sciences Investors in the fourth quarter valued at approximately $3,129,000. Allspring Global Investments Holdings LLC boosted its holdings in shares of abrdn Life Sciences Investors by 16.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 193,484 shares of the company’s stock valued at $2,455,000 after acquiring an additional 27,433 shares in the last quarter. Ameriprise Financial Inc. boosted its holdings in shares of abrdn Life Sciences Investors by 7.5% in the fourth quarter. Ameriprise Financial Inc. now owns 153,396 shares of the company’s stock valued at $1,999,000 after acquiring an additional 10,742 shares in the last quarter. Finally, 180 Wealth Advisors LLC boosted its holdings in shares of abrdn Life Sciences Investors by 0.9% in the first quarter. 180 Wealth Advisors LLC now owns 136,122 shares of the company’s stock valued at $1,727,000 after acquiring an additional 1,247 shares in the last quarter. Institutional investors own 32.21% of the company’s stock.

Insider Buying and Selling

In related news, major shareholder Saba Capital Management, L.P. sold 11,419 shares of the stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $12.71, for a total transaction of $145,135.49. Following the completion of the sale, the insider directly owned 3,017,539 shares of the company’s stock, valued at $38,352,920.69. This represents a 0.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 10.06% of the stock is currently owned by corporate insiders.

abrdn Life Sciences Investors Trading Up 0.2%

abrdn Life Sciences Investors stock opened at $13.70 on Friday. The firm has a 50 day simple moving average of $13.06 and a 200-day simple moving average of $12.88. abrdn Life Sciences Investors has a 12-month low of $10.55 and a 12-month high of $15.90.

abrdn Life Sciences Investors Cuts Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Friday, August 22nd will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, August 22nd. This represents a $1.68 annualized dividend and a yield of 12.3%.

About abrdn Life Sciences Investors

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.